Gemcabene calcium

Research use only, not for human use.

Gemcabene (PD-72953, PD72953) is a first-in-class lipid-lowering agent and activator of PARP.

Gemcabene (PD-72953, PD72953) is a first-in-class lipid-lowering agent and activator of PARP; down-regulates acute-phase C-reactive protein via C/EBP-δ-mediated transcriptional mechanism, inhibits IL-6 plus IL-1β-induced CRP production in a concentration-dependent manner in human hepatoma cells, reaching 70% inhibition at 2 mM; lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), attenuates osteoarthritis and pain in animal models of arthritis and Pain.Hypercholesterolemia Phase 2 Clinical.

Gemcabene calcium (PD-72953 calcium) significantly downregulates hepatic mRNA markers of inflammation (TNF-α, MCP-1, MIP-1β, CCR5, CCR2, NF-κB), lipogenesis and lipid modulation (ApoC-III, ACC1, ADH-4, Sulf-2), and fibrosis (TIMP-1 and MMP-2).

——

PD-72953 | PD72953

Cell Cycle/DNA Damage

PARP

PARP

Cardiovascular Disease

Hypercholesterolemia

209789-08-2

340.473

C16H28CaO5

>98% (HPLC)

H2O : 33.33 mg/mL 97.89 mM

CC(C)(CCCCOCCCCC(C)(C)C(=O)[O-])C(=O)[O-].[Ca+2]

6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid calcium salt

(-20℃)

With Ice Pack

≥ 2 years